Clinical Trial Update: 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL [Phase 1]

View source ↗

Summary

Phase 1 trial of 90Y-ibritumomab tiuxetan with high-dose chemotherapy and autologous transplantation in relapsed or resistant non-Hodgkin lymphoma; study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Stanford University | Conditions: Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT) | Phase 1 | Status: COMPLETED